Bo Hjorth Bentzen

Bo Hjorth Bentzen

Associate Professor


  1. Published

    A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation

    Yfanti, C., Vestbjerg, B., van't Westende, J., Edvardsson, N., Monfort, L. M., Olesen, Morten Steen Salling, Bentzen, Bo Hjorth, Grunnet, Morten, Eveleens Maarse, B. C., Diness, Jonas Goldin, Kemme, M. J. B., Sørensen, U., Moerland, M., van Esdonk, M. J., Klaassen, E. S., Gal, P. & Holst, A. G., 2024, In: British Journal of Clinical Pharmacology. 90, 4, p. 1027-1035

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 13529